vs
Side-by-side financial comparison of QMMM Holdings Ltd (QMMM) and Instil Bio, Inc. (TIL). Click either name above to swap in a different company.
Instil Bio, Inc. is the larger business by last-quarter revenue ($2.2M vs $2.0M, roughly 1.1× QMMM Holdings Ltd). QMMM Holdings Ltd runs the higher net margin — -7.1% vs -365.3%, a 358.2% gap on every dollar of revenue.
Instil Bio Inc. is a clinical-stage biotechnology company focused on developing innovative tumor-infiltrating lymphocyte (TIL) therapies for patients with difficult-to-treat advanced solid tumors. It operates in the immuno-oncology segment, serving patient populations that show limited response to existing standard cancer treatment options.
QMMM vs TIL — Head-to-Head
Income Statement — Q2 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $2.0M | $2.2M |
| Net Profit | $-146.1K | $-8.2M |
| Gross Margin | 27.1% | — |
| Operating Margin | -6.5% | -426.3% |
| Net Margin | -7.1% | -365.3% |
| Revenue YoY | — | -19.2% |
| Net Profit YoY | — | 31.1% |
| EPS (diluted) | — | $-1.13 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | — | $2.2M | ||
| Q3 25 | — | $2.2M | ||
| Q2 25 | — | $2.2M | ||
| Q1 25 | $2.0M | $2.2M | ||
| Q4 24 | — | $2.8M | ||
| Q3 24 | — | $1.5M | ||
| Q2 24 | — | $0 | ||
| Q1 24 | $1.3M | $0 |
| Q4 25 | — | $-8.2M | ||
| Q3 25 | — | $-13.6M | ||
| Q2 25 | — | $-21.4M | ||
| Q1 25 | $-146.1K | $-28.2M | ||
| Q4 24 | — | $-11.9M | ||
| Q3 24 | — | $-23.0M | ||
| Q2 24 | — | $-14.9M | ||
| Q1 24 | $-612.0K | $-24.3M |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | 27.1% | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | 24.1% | — |
| Q4 25 | — | -426.3% | ||
| Q3 25 | — | -670.0% | ||
| Q2 25 | — | -1045.5% | ||
| Q1 25 | -6.5% | -1363.2% | ||
| Q4 24 | — | -426.1% | ||
| Q3 24 | — | -1582.8% | ||
| Q2 24 | — | — | ||
| Q1 24 | -46.2% | — |
| Q4 25 | — | -365.3% | ||
| Q3 25 | — | -606.0% | ||
| Q2 25 | — | -954.2% | ||
| Q1 25 | -7.1% | -1257.8% | ||
| Q4 24 | — | -428.8% | ||
| Q3 24 | — | -1541.9% | ||
| Q2 24 | — | — | ||
| Q1 24 | -45.5% | — |
| Q4 25 | — | $-1.13 | ||
| Q3 25 | — | $-2.01 | ||
| Q2 25 | — | $-3.24 | ||
| Q1 25 | — | $-4.32 | ||
| Q4 24 | — | $-1.82 | ||
| Q3 24 | — | $-3.54 | ||
| Q2 24 | — | $-2.29 | ||
| Q1 24 | — | $-3.74 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $167.9K | $6.6M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $3.9M | $113.9M |
| Total Assets | $4.5M | $203.5M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $6.6M | ||
| Q3 25 | — | $5.8M | ||
| Q2 25 | — | $7.7M | ||
| Q1 25 | $167.9K | $15.4M | ||
| Q4 24 | — | $8.8M | ||
| Q3 24 | — | $6.7M | ||
| Q2 24 | — | $6.8M | ||
| Q1 24 | $218.9K | $5.5M |
| Q4 25 | — | $113.9M | ||
| Q3 25 | — | $120.4M | ||
| Q2 25 | — | $131.7M | ||
| Q1 25 | $3.9M | $144.9M | ||
| Q4 24 | — | $169.4M | ||
| Q3 24 | — | $176.3M | ||
| Q2 24 | — | $195.0M | ||
| Q1 24 | $-1.1M | $205.8M |
| Q4 25 | — | $203.5M | ||
| Q3 25 | — | $211.8M | ||
| Q2 25 | — | $231.0M | ||
| Q1 25 | $4.5M | $237.4M | ||
| Q4 24 | — | $263.6M | ||
| Q3 24 | — | $272.6M | ||
| Q2 24 | — | $294.3M | ||
| Q1 24 | $1.3M | $306.3M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-301.2K | $-7.1M |
| Free Cash FlowOCF − Capex | — | — |
| FCF MarginFCF / Revenue | — | — |
| Capex IntensityCapex / Revenue | — | — |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $-7.1M | ||
| Q3 25 | — | $-10.6M | ||
| Q2 25 | — | $-14.8M | ||
| Q1 25 | $-301.2K | $-4.2M | ||
| Q4 24 | — | $-10.6M | ||
| Q3 24 | — | $-20.1M | ||
| Q2 24 | — | $-10.6M | ||
| Q1 24 | $-184.6K | $-14.4M |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 0.0% | ||
| Q3 24 | — | 0.0% | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
